<DOC>
	<DOCNO>NCT01261429</DOCNO>
	<brief_summary>The purpose study explore efficacy nilotinib treatment patient progressive relapse pigmented villo-nodular synovitis / tenosynovial giant cell tumour ( PVNS/TGCT ) treat surgery . The primary objective study determine efficacy 12 week ( 3 month ) nilotinib treatment measure non progression rate ( Complete response + Partial Response + Stable disease accord Response Evaluation Criteria In Solid Tumours - RECIST version 1.1 ) patient progressive relapse PVNS/TGCT treat surgery . study international , multicentre , non-randomized , open-label phase II clinical trial Bayesian design . A maximum sample size 50 patient include study</brief_summary>
	<brief_title>Study Nilotinib Efficacy Pigmented Villo-Nodular Synovitis/ Tenosynovial Giant Cell Tumour ( PVNS/TGCT )</brief_title>
	<detailed_description>A key secondary objective study determine efficacy 24 week ( 6 month ) nilotinib treatment measure non progression rate ( Complete response + Partial Response + Stable disease accord Response Evaluation Criteria In Solid Tumours - RECIST version 1.1 ) patient progressive relapse PVNS/TGCT treat surgery . This key secondary objective define purpose analysis ( describe protocol ) pool data PVNS study similar concomitant study conduct US Australia . The secondary objective : To evaluate efficacy nilotinib accord : - The objective tumour response rate ( Complete response + Partial Response accord RECIST version 1.1 ) 12 week treatment - The duration treatment response - The best overall response obtain study - The progression-free survival ( PFS ) - The time progression ( TTP ) - The time treatment failure ( TTF ) - The proportion patient operable tumour nilotinib exposure accord investigator evaluation - The description concomitant treatment use - The correlation trough level nilotinib objective tumour response To assess safety nilotinib PVNS/TGCT patient An exploratory objective study study relationship objective tumour response follow tumour characteristic ( tissue collect prior surgery , biopsy , upon specific acceptance patient ; tissue available prior surgery , biopsy do visit 2 ) : Presence COL6A3/CSF1 fusion gene Presence M-CSF , CSF1R , KIT , PDGFRA B immunohistochemistry Presence phosphorylated c-fms tumour sample Activation PI3K/Akt/mTor pathway , presence activate mutation ra , potential molecular alteration</detailed_description>
	<mesh_term>Synovitis</mesh_term>
	<mesh_term>Giant Cell Tumors</mesh_term>
	<mesh_term>Synovitis , Pigmented Villonodular</mesh_term>
	<criteria>Age &gt; 18 year Histologically confirm diagnosis inoperable progressive relapse PVNS/TGCT OR resectable tumour request mutilate surgery Demonstrated progressive disease last 12 month At least one measurable site disease MRI/CT scan accord RECIST criterion ( RECIST version 1.1 ) base investigator 's assessment WHO Performance status 0 , 1 2 Adequate organ , electrolyte marrow function , define follow : serum bilirubin &gt; =1.5 x ULN , ALT AST &lt; = 2.5 x ULN , serum creatinine &lt; = 1.5 x ULN creatinine clearance &gt; = 50 mL/min , absolute neutrophil count ( ANC ) &gt; = 1.5x109/L , platelet &gt; = 100x109/L , serum lipase &lt; =1.5 x ULN , magnesium ≥ low limit normal ( LLN ) potassium ≥ LLN Prior adequate physical examination include weight , height , ECOG PS vital sign ( systolic diastolic blood pressure , heart rate least 5 minute supine position ) Signed write informed consent form Covered medical insurance ( country applicable ) Pregnant lactate female female childbearing potential employ adequate contraception study three month follow termination study Known hypersensitivity nilotinib excipients , galactose intolerance , lactase deficiency glucosegalactose malabsorption prior enrollment Acute chronic uncontrolled liver disease , severe renal disease Impaired cardiac function , include : LVEF &lt; 50 % institutional low limit normal range ( whichever high ) determine echocardiogram MUGA scan History sign prior myocardial infarction History unstable angina Congenital long QT prolongation Personal history unexplained syncope QTc interval ≥ 450 msec screen ECG Other clinically significant heart disease ( e.g . bradycardia , congestive heart failure uncontrolled hypertension ) Patient family history long QT syndrome , unexplained syncope unexplained sudden death Patients severe and/or uncontrolled concurrent medical disease opinion investigator could cause unacceptable safety risk compromise compliance protocol e.g . uncontrolled diabetes , active uncontrolled infection , history pancreatitis History noncompliance medical regimen Concomitant treatment medicinal product induce CYP3A4 ( e.g . dexamethasone , phenytoin , carbamazepine , rifampicin , phenobarbital St. John 's Wort ) , inhibit CYP3A4 activity ( e.g . ketoconazole , itraconazole , voriconazole , erythromycin , clarithromycin , telithromycin ) Concomitant treatment warfarin Concomitant treatment antiarrhythmic drug ( e. g. amiodarone , sotalol , disopyramide , quinidine , procainamide ) medication prolongs QT interval ( e.g . chloroquine , chlorpromazine , domperidone , droperidol , halofantrine , haloperidol , methadone , pentamidine , pimozide , thioridazine ) Prior treatment imatinib except progression demonstrate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Pigmented villonodular synovitis</keyword>
	<keyword>tenosynovial giant cell tumour</keyword>
	<keyword>nilotinib</keyword>
</DOC>